Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Congress Asset Management Co. trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,959,736 shares of the biopharmaceutical company's stock after selling 473,843 shares during the period. Congress Asset Management Co. owned approximately 1.54% of Halozyme Therapeutics worth $93,695,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the 4th quarter valued at $29,000. Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $57,000. FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $65,000. CWM LLC boosted its position in shares of Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company's stock worth $88,000 after purchasing an additional 668 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Halozyme Therapeutics by 173.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,028 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $61.11.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded down $0.13 on Wednesday, hitting $57.77. The company's stock had a trading volume of 2,236,381 shares, compared to its average volume of 1,306,070. Halozyme Therapeutics, Inc. has a 52-week low of $35.50 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a fifty day moving average price of $52.69 and a 200-day moving average price of $54.51. The company has a market capitalization of $7.35 billion, a P/E ratio of 19.13, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.70% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.